4//SEC Filing
KUGELMAN LARRY 4
Accession 0001209191-10-048111
CIK 0000930184other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 8:40 PM ET
Size
7.8 KB
Accession
0001209191-10-048111
Insider Transaction Report
Form 4
KUGELMAN LARRY
Director
Transactions
- Disposition to Issuer
Nonqualified Stock Option (right to buy)
2010-09-28−10,000→ 0 totalExercise: $8.12Exp: 2010-10-18→ Common Stock (10,000 underlying) - Disposition to Issuer
Common Stock
2010-09-28−55,589→ 0 total
Footnotes (2)
- [F1]51,565 restricted stock units disposed pursuant to merger agreement between issuer and Biovail Corporation, among others, in exchange for 144,262 Valeant Pharmaceuticals International, Inc. (formerly known as Biovail Corporation) restricted stock units, on the same terms and conditions. Remaining 4,024 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 8,534 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was $26.00 per share.
- [F2]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 27,977 shares of Valeant Pharmaceuticals International, Inc. common stock for $2.90 per share.
Documents
Issuer
VALEANT PHARMACEUTICALS INTERNATIONAL
CIK 0000930184
Entity typeother
Related Parties
1- filerCIK 0001201981
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 8:40 PM ET
- Size
- 7.8 KB